Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.47 |
| ▸ | DAO | P14920 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463002 | 1.00 | HCAR2 (0.47) | HCAR2DAOALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL13305777 | 0.85 | DAO (0.42) | HCAR2DAOALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL8948187 | 0.85 | DAO (0.42) | HCAR2DAOALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL609542 | 0.81 | JUN (0.54) | HCAR2DAOALDH1A1SMN1; SMN2HDAC1 | |
| SCHEMBL5204964 | 0.81 | HCAR2 (0.45) | HCAR2ALDH1A1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL5204967 | 0.81 | HCAR2 (0.45) | HCAR2ALDH1A1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL8987306 | 0.80 | MAPT (0.55) | ALDH1A1SMN1; SMN2KMT2AHPGDLMNA | |
| SCHEMBL18639716 | 0.79 | DAO (0.38) | HCAR2DAOHDAC3HDAC4HDAC1 | |
| SCHEMBL18874102 | 0.79 | DAO (0.39) | DAOLMNAPTGS1PTGS2ALOX5 | |
| SCHEMBL380483 | 0.78 | HCAR2 (0.48) | HCAR2ALDH1A1MAPK1KMT2AEIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118165002-A | Polycyclic compounds and methods of use thereof | 桑诺维恩药品公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3252057-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-10-15 | — | — | US | disclosed |
| CN-111560025-A | Polycyclic compounds and methods of use thereof | 桑诺维恩药品公司 | 2020-08-21 | — | — | CN | disclosed |
| CN-106883246-B | Polycyclic compounds and methods of use thereof | 桑诺维恩药品公司 | 2020-05-29 | — | — | CN | disclosed |
| US-20190125722-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-10085968-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2018-10-02 | — | — | US | disclosed |
| EP-3252057-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20070060607-A1 | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | BARTKOVITZ DAVID J | 2007-03-15 | — | — | US | disclosed |
| WO-2007019884-A1 | NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
| EP-1556053-A4 | ANTIINFLAMMATION AGENTS | AMGEN INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050256154-A1 | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides | LUK KIN-CHUN | 2005-11-17 | — | — | US | disclosed |
| EP-1556053-A1 | ANTIINFLAMMATION AGENTS | Amgen Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041285-A1 | ANTIINFLAMMATION AGENTS | AMGEN INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097485-A1 | Antiinflammation agents | TULARIK INC. | 2004-05-20 | — | — | US | disclosed |
| US-4948796-A | TREATING CEREBO-VASCULARE DISEASES | TOYAMA CHEMICAL CO., LTD. (JP) | 1990-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125722-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | HCAR2 810/4885DAO 1113/4885ALDH1A1 919/4885 |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | HCAR2 810/4885DAO 1113/4885ALDH1A1 919/4885 |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | HCAR2 810/4885DAO 1113/4885ALDH1A1 919/4885 |
| US-20050256154-A1 | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides | FGFR3, FGFR4, FGFR1 | HCAR2 389/4885DAO 1844/4885ALDH1A1 364/4885 |
| US-20070060607-A1 | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | BRAF, RAF1, MAP3K7 | HCAR2 1095/4885DAO 1687/4885ALDH1A1 933/4885 |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | GRIN2C, NLN, COMT | HCAR2 810/4885DAO 1113/4885ALDH1A1 919/4885 |
| US-10085968-B2 | Multicyclic compounds and methods of use thereof | GRIN2A, AVPR1A, GRIN2C | HCAR2 787/4885DAO 1971/4885ALDH1A1 919/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | HCAR2 3637/4885DAO 1438/4885ALDH1A1 2972/4885 |
| US-20040097485-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | HCAR2 119/4885DAO 1444/4885ALDH1A1 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.